Success at a Glance
- Improved trial success rates in Alzheimer’s research.
- Reduced screening costs by 40%.
- Expanded globally with €14M in funding.
About iLOF
iLOF is a healthcare innovator from Portugal. It uses AI and photonics to transform drug development. The company’s technology enhances patient selection for clinical trials, focusing on diseases like Alzheimer’s, ovarian cancer, and COVID-19.
EIT and Investor Support
- EIT Programs: Backed by EIT Jumpstarter and EIT Health Wild Card.
- Global Investors: Secured funding from EIC, M12, and OXFO Fund.
- Growth Enabler: Support fueled international expansion and innovation.
Key Milestones
- Raised €14M in funding.
- Offices in Porto, New York, and London.
- A team of 31 employees drives solutions globally.
The Impact
iLOF’s platform optimizes clinical trials with AI-driven precision. It reduces costs and time while ensuring trials involve the most qualified patients. This innovation supports personalized treatments for complex diseases, reshaping healthcare worldwide.